RVTY
HealthcareRevvity, Inc.
$102.06
+$3.91 (+3.98%)
Jan 5, 2026
Price History (1Y)
Analysis
Revvity, Inc. is a healthcare company operating in the diagnostics and research industry with a significant scale, boasting a market capitalization of $11.85B, annual revenue of $2.81B, and a workforce of 11,000 employees. The company demonstrates robust financial health, with notable profitability metrics including a gross margin of 55.2%, an operating margin of 13.8%, and a profit margin of 8.4%. Furthermore, Revvity has generated substantial returns on equity (3.0%) and assets (2.1%). The balance sheet shows a manageable debt-to-equity ratio of 45.68 and a healthy cash position of $931.39M, offset by a significant debt load of $3.37B. Revvity's valuation is characterized by a relatively high price-to-earnings ratio of 50.52 (TTM) and 19.26 (forward), which may indicate market expectations for growth. The company has experienced year-over-year revenue growth of 2.2% and earnings contraction of 47.4%. Additionally, the dividend yield is significant at 29.0%, with a payout ratio of 14.4%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Revvity, Inc.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services; and instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, screening newborns for rare genetic conditions, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BioQule, BoBs, chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPatternTM, Evolution Evoya, explorer, Fontus, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Omni Bead Ruptor, Omni Bead Ruptor Elite, Omni Tip, Pannoramic, Panthera Puncher, PG-Seq, PG-Find, PreNAT II, Prime, Protein Clear, ProteinEXact, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord, VICTOR2D, and Zephyr names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $11.85B
- P/E Ratio
- 50.52
- 52-Week High
- $128.29
- 52-Week Low
- $81.36
- Avg Volume
- 1.39M
- Beta
- 1.05
- Dividend Yield
- 29.00%
Company Info
- Industry
- Diagnostics & Research
- Exchange
- NYQ
- Country
- United States
- Employees
- 11,000